Cargando…

Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS-CoV-2 Natural Infection

SARS-CoV-2 antibody assays are crucial in managing the COVID-19 pandemic. Approved mRNA COVID-19 vaccines are well known to induce a serum antibody responses against the spike protein and its RBD. Mucosal immunity plays a major role in the fight against COVID-19 directly at the site of virus entry;...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guerrieri, Mariapia, Francavilla, Beatrice, Fiorelli, Denise, Nuccetelli, Marzia, Passali, Francesco Maria, Coppeta, Luca, Somma, Giuseppina, Bernardini, Sergio, Magrini, Andrea, Di Girolamo, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708818/ https://www.ncbi.nlm.nih.gov/pubmed/34960244 http://dx.doi.org/10.3390/vaccines9121499

Ejemplares similares

Correction: Guerrieri et al. Nasal and Salivary Mucosal Humoral Immune Response Elicited by mRNA BNT162b2 COVID-19 Vaccine Compared to SARS-CoV-2 Natural Infection. Vaccines 2021, 9, 1499
por: Guerrieri, Mariapia, et al.
Publicado: (2023)

Importance of nasal secretions in the evaluation of mucosal immunity elicited by mRNA BNT162b2 COVID-19 Vaccine
por: Francavilla, Beatrice, et al.
Publicado: (2022)

Evaluation of the accuracy in the mucosal detection of anti-SARS-CoV-2 antibodies in nasal secretions and saliva
por: Fiorelli, Denise, et al.
Publicado: (2023)

Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19
por: Coppeta, Luca, et al.
Publicado: (2021)

Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 mRNA Vaccine
por: Coppeta, Luca, et al.
Publicado: (2022)

Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly
por: Dalla Gasperina, Daniela, et al.
Publicado: (2023)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers
por: Coppeta, Luca, et al.
Publicado: (2021)

Decline of immune humoral response after BNT162b2 vaccine
por: Ferri, Sonia, et al.
Publicado: (2022)

Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients
por: Guarino, Maria, et al.
Publicado: (2022)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
por: Miyazaki, Ryoichi, et al.
Publicado: (2023)

The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)
por: Woldemeskel, Bezawit A, et al.
Publicado: (2021)

Evaluation of the Effectiveness of BNT162b2 Primary Vaccination and Booster Dose to SARS-CoV-2 in Eliciting Stable Mucosal Immunity
por: Lambiase, Alessandro, et al.
Publicado: (2022)

Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients
por: Pitzalis, Maristella, et al.
Publicado: (2021)

Humoral response to 2-dose BNT162b2 mRNA vaccine for Covid-19 in liver transplant recipients
por: Guarino, M., et al.
Publicado: (2022)

Humoral response to 2-dose BNT162b2 mRNA vaccine for COVID-19 in liver transplant recipients
por: Guarino, Maria, et al.
Publicado: (2022)

Systemic and Mucosal Humoral Immune Response Induced by Three Doses of the BNT162b2 SARS-CoV-2 mRNA Vaccines
por: Mancuso, Roberta, et al.
Publicado: (2022)

Humoral Serologic Response to the BNT162b2 Vaccine Afterallogeneic Haematopoietic Cell Transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2021)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
por: Kitamura, Mineaki, et al.
Publicado: (2022)

Aspects of Humoral Immunity after Vaccination with Bnt162b2: A Small Study
por: GIUBELAN, LUCIAN-ION, et al.
Publicado: (2022)

Humoral and Cellular Immunogenicity of 3 Doses of BNT162b2 in Children With Kidney Diseases
por: Leung, Daniel, et al.
Publicado: (2023)

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients
por: Azzi, Lorenzo, et al.
Publicado: (2021)

Global Policy to Reduce the Incidence of Infection Spreading in Non-Vaccinated Healthcare Workers: A Literature Review
por: Ferrari, Cristiana, et al.
Publicado: (2022)

OC.15.2 HUMORAL RESPONSE TO 2-DOSE BNT162B2 MRNA VACCINE FOR COVID-19 IN LIVER TRANSPLANT RECIPIENTS
por: Guarino, M., et al.
Publicado: (2022)

Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2022)

Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis
por: Dekervel, Marine, et al.
Publicado: (2021)

Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients
por: Agur, Timna, et al.
Publicado: (2022)

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
por: Shostak, Yael, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
por: Levin, Einav G., et al.
Publicado: (2021)

Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer
por: Di Noia, V., et al.
Publicado: (2022)

Serum C reactive protein predicts humoral response after BNT162b2 booster administration
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
por: Costard-Jäckle, Angelika, et al.
Publicado: (2022)

Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2
por: Rammauro, Florencia, et al.
Publicado: (2022)

Humoral and Cellular Immunity Are Significantly Affected in Renal Transplant Recipients, following Vaccination with BNT162b2
por: Fylaktou, Asimina, et al.
Publicado: (2023)

Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine
por: Azzi, Lorenzo, et al.
Publicado: (2023)

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen
por: Baek, Yae Jee, et al.
Publicado: (2023)

A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses
por: Tauzin, Alexandra, et al.
Publicado: (2022)

Night Shift Work Is Associated with Reduced Rate of Humoral Response Following Vaccination for HBV
por: Coppeta, Luca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1nkes80dvqc2u15emneovcg415